PPC in medical terms most commonly stands for primary peritoneal cancer, a rare malignancy that starts in the thin tissue lining the inside of the abdomen. The abbreviation also has other meanings in medicine, including polyene phosphatidylcholine (a liver-protective supplement) and progressive patient care (a hospital care level). Which definition applies depends on context, but primary peritoneal cancer is the most frequent clinical use.
Primary Peritoneal Cancer
Primary peritoneal cancer (PPC) originates in the peritoneum, the membrane that lines the abdominal cavity and covers the organs inside it. Unlike secondary peritoneal cancers, which spread to the peritoneum from tumors in the ovaries, colon, or stomach, PPC starts in the peritoneal tissue itself. The cancer develops when the flat cells lining this membrane undergo a transformation and begin growing uncontrollably. Because of this cell type, PPC behaves almost identically to a common form of ovarian cancer called serous carcinoma.
This similarity to ovarian cancer is so strong that PPC can even develop in women who have had their ovaries removed. The key distinction is that with PPC, the ovaries are either normal in size or show only minimal tumor involvement. Formal diagnostic criteria from the Gynecologic Oncology Group require that any tumor on the ovary measure less than 5 by 5 millimeters and that the bulk of cancer be located outside the ovaries entirely.
How PPC Differs From Ovarian Cancer
PPC and epithelial ovarian cancer share the same cell appearance under a microscope, respond to the same chemotherapy drugs, and are staged using the same system. The practical difference is where the cancer starts. In ovarian cancer, the primary mass is on one or both ovaries. In PPC, the cancer is spread across the peritoneal surfaces with little to no ovarian involvement. Importantly, it is not possible to have stage I peritoneal cancer, because by definition the disease has already spread across the peritoneal lining at the time of diagnosis.
The two cancers also share a genetic link. About 28% of women with PPC carry a BRCA1 or BRCA2 gene mutation, nearly identical to the 30% rate seen in advanced ovarian cancer. This means PPC is considered part of the hereditary breast-ovarian cancer syndrome, and women with known BRCA mutations have an elevated risk of developing it.
Symptoms and How It Is Found
PPC tends to cause vague symptoms that overlap with many less serious conditions, which often delays diagnosis. The most common initial complaint is abdominal fullness or bloating, caused by fluid buildup in the abdomen (called ascites). Other symptoms include abdominal pain, a noticeable swelling or mass in the belly, and in some cases shortness of breath from fluid collecting around the lungs.
Less typical presentations have been documented. Some patients first notice a lump in the groin, while others develop unexplained weakness or numbness in a limb from tumor pressing on nerves. Because the symptoms are so nonspecific, most people are diagnosed at an advanced stage.
Diagnosis typically involves a CT scan to visualize fluid and tumor deposits across the abdomen, along with a blood test for a protein called CA-125. CA-125 is considered the most useful tumor marker for PPC and is also used to track whether treatment is working or the disease is coming back. A tissue biopsy confirms the diagnosis and rules out ovarian cancer as the source.
Staging
PPC is staged using the same FIGO system applied to ovarian and fallopian tube cancers. Because the cancer has already spread across the peritoneum at diagnosis, it starts at stage II at minimum. Most patients are diagnosed at stage III, meaning the cancer has spread beyond the pelvis to the upper abdomen or nearby lymph nodes. Stage IV is assigned when the cancer reaches distant organs like the liver or lungs, or when fluid around the lungs tests positive for cancer cells.
Treatment
The standard approach combines surgery and chemotherapy, following the same protocols used for advanced ovarian cancer. The surgical goal is cytoreductive surgery, which involves removing as much visible tumor as possible from the abdominal cavity, including stripping affected portions of the peritoneum and resecting any involved organs. The aim is to leave behind only microscopic disease.
Chemotherapy is given either before surgery (to shrink tumors and make removal easier) or after surgery to eliminate remaining cancer cells. For patients whose tumors respond well to initial chemotherapy, a specialized technique called HIPEC may be considered. This involves bathing the abdominal cavity in heated chemotherapy solution during surgery, which allows higher drug concentrations to reach the peritoneal surfaces directly. Clinical guidelines recommend considering HIPEC for patients with primary peritoneal carcinoma who have at least stable disease after initial chemotherapy and whose surgeon achieves complete or near-complete tumor removal.
Survival and Outlook
Outcomes for PPC depend heavily on how much tumor can be removed surgically and how the cancer responds to chemotherapy. For patients who undergo the combination of cytoreductive surgery and HIPEC, overall survival rates in one study were 81% at one year, 74% at two years, and 53% at five years. These numbers span multiple types of peritoneal cancer, and individual outcomes vary based on the specific cancer type, stage, and how completely the surgeon can remove visible disease. Because PPC is closely related to ovarian cancer, advances in ovarian cancer treatment, including targeted therapies for BRCA mutation carriers, also apply to many PPC patients.
Other Medical Meanings of PPC
Polyene Phosphatidylcholine
In pharmacology, PPC refers to polyene phosphatidylcholine, a naturally occurring fat molecule that is a building block of cell membranes. It is widely used as a liver-protective supplement, particularly for patients with liver disease or those experiencing liver toxicity from chemotherapy. PPC works by reducing cellular stress and inflammation in liver tissue. It is considered non-toxic and is sometimes recommended as a dietary supplement during cancer treatment to help buffer the liver against damage from chemotherapy drugs.
Progressive Patient Care
In hospital and nursing terminology, PPC stands for progressive patient care, a level of care between a general medical floor and an intensive care unit. The concept originated in the 1970s for patients recovering from heart attacks and has since expanded. Progressive care patients are acutely ill and at elevated risk of becoming unstable, but they are moderately stable at the time. They require closer monitoring and more frequent nursing attention than a standard hospital patient but do not need the full resources of an ICU. Nurses in these units can earn a specialized certification called the PCCN (Progressive Care Certified Nurse).